Evidence map›Paper›PMID 37522508›Full record

ArticleSkin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)2023

Development of a method for evaluating skin dullness: A mathematical model explaining dullness by the color, optical properties, and microtopography of the skin.

Alif Meem Nurani, Kumiko Kikuchi, Masato Iino, Yutaka Shirasugi, Aska Sonoki, Takako Fujimura, Kiyotaka Hasegawa, Takako Shibata

Open access · hybridAbstract read
In one paragraph

Article in Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. 2 kDa Hyaluronic Acid Reduces Blemishes and Sagging in Human Facial Skin.Clinical, cosmetic and investigational dermatology · 2025
    Article
  7. Development of a method for evaluating skin dullness: A mathematical model explaining dullness by the color, optical properties, and microtopography of the skin.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Alif Meem NuraniShiseido Co., Ltd., MIRAI Technology Institute, 1-2-11, Takashima, Nishi-ku, Yokohama, Japan.ORCID https://orcid.org/0000-0002-3749-6682
Kumiko KikuchiShiseido Co., Ltd., MIRAI Technology Institute, 1-2-11, Takashima, Nishi-ku, Yokohama, Japan.ORCID https://orcid.org/0000-0002-7365-3243
Masato IinoShiseido Co., Ltd., MIRAI Technology Institute, 1-2-11, Takashima, Nishi-ku, Yokohama, Japan.
Yutaka ShirasugiShiseido Co., Ltd., MIRAI Technology Institute, 1-2-11, Takashima, Nishi-ku, Yokohama, Japan.
Aska SonokiShiseido Co., Ltd., MIRAI Technology Institute, 1-2-11, Takashima, Nishi-ku, Yokohama, Japan.
Takako FujimuraShiseido Co., Ltd., Brand Value R&D Institute, 1-2-11, Takashima, Nishi-ku, Yokohama, Japan.
Kiyotaka HasegawaShiseido Co., Ltd., MIRAI Technology Institute, 1-2-11, Takashima, Nishi-ku, Yokohama, Japan.
Takako ShibataShiseido Co., Ltd., MIRAI Technology Institute, 1-2-11, Takashima, Nishi-ku, Yokohama, Japan.
Mirai Hospital · JPMeiko (United Kingdom) · GBShiseido Group (Japan) · JP

Funding

Shiseido Co. Ltd
6 · The paper itself

Abstract

backgroundSkin dullness has long been a major concern of Japanese women. It is usually evaluated and judged visually by experts. Although several factors are recognized to play a role, it is unclear to what extent such physiological characteristics contribute to skin dullness. The purpose of this study is to establish an objective method for evaluation, which will assist in developing cosmetics products targeting skin dullness.

methodsWe conducted a skin measurement study on 50 Japanese women in their 30-50s, where skin dullness was visually assessed by a group of experts to obtain an average dullness score, and several skin parameters were obtained. We then developed a regression model that explains the visual assessment score using these physiological parameters.

resultsThe results of partial least squares analysis of the dullness perception and physiological characteristics showed that skin dullness can be defined by colorimetric, optical, and skin surface microtopography parameters. Additionally, the contribution of each parameter to the model was determined. Our results suggest that dullness perception is highly affected by the melanin content and yellowness of the skin, followed by skin reddishness, roughness, and translucency score, whereas glossiness has less effect. Strikingly, the contribution ratio of each parameter varied among age groups. Furthermore, we confirmed that the predicted value of skin dullness increases with age.

conclusionOur results will help the design of cosmetics targeting factors specific to age groups in developing effective solutions for skin dullness.

Indexed as

CosmeticsSkinColorimetryFemaleHumansModels, TheoreticalSurface PropertiesCosmeticsglossinessmelaninoptical propertiespartial least squares analysisskin dullnessskin parametersskin roughnesstranslucencyvisual assessment

Identifiers

PMID37522508
PMCPMC10337531
OpenAlexW4384070489

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.